Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002662 · ClinicalTrials.gov registry record · Phase 3
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Aventis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00002662: Completed Phase 3 study of Breast Cancer, sponsored by Aventis Pharmaceuticals.
NCT00002662 is a Phase 3 study of Breast Cancer that has completed, run by Aventis Pharmaceuticals. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002662, a Phase 3 study of Breast Cancer, has completed, sponsored by Aventis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG paclitaxel
Study Locations (20)
Arkansas
- Highlands Oncology Group, P.A. - Fayetteville - Fayetteville
- Northeast Arkansas Clinic - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
California
- California Cancer Care, Inc. - Greenbrae
- Green Cancer Center at Scripps Clinic - La Jolla
- Sidney Kimmel Cancer Center - San Diego
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Southfield Oncology Institute, Inc. - Southfield
Alabama
- Montclair Regional Cancer Center - Birmingham
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Denver
Connecticut
- Norwich Cancer Center - Norwich
District of Columbia
- George Washington University Medical Center - Washington D.C.
Florida
- Baptist Regional Cancer Institute - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Start Date | 1994-08 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002662
The ClinicalTrials.gov registry entry for NCT00002662 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Aventis Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00002662 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Arkansas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT00002662 about?
NCT00002662 is a clinical study titled "Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxe...
What is the current status of trial NCT00002662?
This trial is currently completed. It is a Phase 3 study. The study started on 1994-08. Estimated completion is 2004-06.
What conditions does trial NCT00002662 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00002662?
The interventions under investigation include: docetaxel (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00002662?
This trial is sponsored by Aventis Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002662 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.